Systemic therapy in metastatic renal cell carcinoma (mRCC) : an evidence-based recommendation of the German interdisciplinary RCC guidelines group
© 2022. The Author(s)..
PURPOSE: The treatment landscape in metastatic renal cell carcinoma (mRCC) has evolved dramatically in recent years. Within the German guideline committee for RCC we evaluated current medical treatments and gave recommendations.
METHODS: A systematic review of published evidence for medical treatment of mRCC was performed (July 2016-August 2019) to cover the duration from last guideline update in 2016. Evidence was graded according to SIGN ( http://www.sign.ac.uk/pdf/sign50.pdf ). Recommendations were made on the basis of a nominal group work with consensus approach and included patient advocates and shareholder of the German RCC treatment landscape. Each recommendation was graded according to its strength as strong recommendation (A) or recommendation (B). Expert statements were given, where appropriate.
RESULTS: Strong first-line recommendations (IA) exist for axitinib + pembrolizumab (all risk categories) and ipilimumab + nivolumab (intermediate or poor risk only). Axitinib + avelumab is a recommended first-line treatment across patients with any risk category (IB). In patients who are not candidates for immune check point inhibitor (ICI) combinations, targeted agents should be offered as an alternative treatment. Subsequent treatment after ICI-based combinations remain ill-defined and no standard of care can be formulated.
CONCLUSION: ICI-based combinations are the first-line standard of care and should be considered accordingly. There is an unmet medical need for pivotal studies that define novel standards in patients with failure of ICI-based combinations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
World journal of urology - 40(2022), 10 vom: 13. Okt., Seite 2381-2386 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Grünwald, V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
31YO63LBSN |
|---|
| Anmerkungen: |
Date Completed 28.09.2022 Date Revised 29.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00345-022-04015-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34085541X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34085541X | ||
| 003 | DE-627 | ||
| 005 | 20231226010425.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00345-022-04015-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1136.xml |
| 035 | |a (DE-627)NLM34085541X | ||
| 035 | |a (NLM)35562599 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Grünwald, V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Systemic therapy in metastatic renal cell carcinoma (mRCC) |b an evidence-based recommendation of the German interdisciplinary RCC guidelines group |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2022 | ||
| 500 | |a Date Revised 29.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a PURPOSE: The treatment landscape in metastatic renal cell carcinoma (mRCC) has evolved dramatically in recent years. Within the German guideline committee for RCC we evaluated current medical treatments and gave recommendations | ||
| 520 | |a METHODS: A systematic review of published evidence for medical treatment of mRCC was performed (July 2016-August 2019) to cover the duration from last guideline update in 2016. Evidence was graded according to SIGN ( http://www.sign.ac.uk/pdf/sign50.pdf ). Recommendations were made on the basis of a nominal group work with consensus approach and included patient advocates and shareholder of the German RCC treatment landscape. Each recommendation was graded according to its strength as strong recommendation (A) or recommendation (B). Expert statements were given, where appropriate | ||
| 520 | |a RESULTS: Strong first-line recommendations (IA) exist for axitinib + pembrolizumab (all risk categories) and ipilimumab + nivolumab (intermediate or poor risk only). Axitinib + avelumab is a recommended first-line treatment across patients with any risk category (IB). In patients who are not candidates for immune check point inhibitor (ICI) combinations, targeted agents should be offered as an alternative treatment. Subsequent treatment after ICI-based combinations remain ill-defined and no standard of care can be formulated | ||
| 520 | |a CONCLUSION: ICI-based combinations are the first-line standard of care and should be considered accordingly. There is an unmet medical need for pivotal studies that define novel standards in patients with failure of ICI-based combinations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Checkpoint inhibitor | |
| 650 | 4 | |a Guideline | |
| 650 | 4 | |a Medical therapy | |
| 650 | 4 | |a Renal cell carcinoma | |
| 650 | 4 | |a Tyrosine kinase inhibitor | |
| 650 | 7 | |a Ipilimumab |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 650 | 7 | |a Axitinib |2 NLM | |
| 650 | 7 | |a C9LVQ0YUXG |2 NLM | |
| 700 | 1 | |a Bergmann, L |e verfasserin |4 aut | |
| 700 | 1 | |a Brehmer, B |e verfasserin |4 aut | |
| 700 | 1 | |a Eberhardt, B |e verfasserin |4 aut | |
| 700 | 1 | |a Kastrati, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Gauler, T |e verfasserin |4 aut | |
| 700 | 1 | |a Gehbauer, G |e verfasserin |4 aut | |
| 700 | 1 | |a Gschwend, J |e verfasserin |4 aut | |
| 700 | 1 | |a Johannsen, M |e verfasserin |4 aut | |
| 700 | 1 | |a Klotz, T |e verfasserin |4 aut | |
| 700 | 1 | |a Protzel, C |e verfasserin |4 aut | |
| 700 | 1 | |a Schenck, M |e verfasserin |4 aut | |
| 700 | 1 | |a Staehler, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of urology |d 1988 |g 40(2022), 10 vom: 13. Okt., Seite 2381-2386 |w (DE-627)NLM07484959X |x 1433-8726 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:10 |g day:13 |g month:10 |g pages:2381-2386 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00345-022-04015-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 10 |b 13 |c 10 |h 2381-2386 | ||